265 related articles for article (PubMed ID: 36439117)
21. Safety of thoracic radiotherapy after PD-(L)1 inhibitor treatment in patients with lung cancer.
Chen Y; Liu X; Huang Z; Zhao K; Wang Y; Ren F; Yu J; Meng X
Cancer Med; 2021 Dec; 10(23):8518-8529. PubMed ID: 34664788
[TBL] [Abstract][Full Text] [Related]
22. The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials.
Lin GF; Xu Y; Lin H; Yang DY; Chen L; Huang LL; Su XS; Xu YX; Zeng YM
Int Immunopharmacol; 2021 Oct; 99():108011. PubMed ID: 34426108
[TBL] [Abstract][Full Text] [Related]
23. The safety of first and subsequent lines of PD-1/PD-L1 inhibitors monotherapy in non-small cell lung cancer patients: a meta-analysis.
Yang Y; Pang P; Xie Z; Wang N; Liang H; Zhao L
Transl Cancer Res; 2020 May; 9(5):3231-3241. PubMed ID: 35117689
[TBL] [Abstract][Full Text] [Related]
24. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis.
Zhu X; Shanzhou Q; Li D; Pang X; Ma D
BMC Cancer; 2021 Nov; 21(1):1195. PubMed ID: 34758782
[TBL] [Abstract][Full Text] [Related]
25. Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials.
Zheng J; Huang B; Xiao L; Wu M; Li J
Front Oncol; 2022; 12():821626. PubMed ID: 36568203
[TBL] [Abstract][Full Text] [Related]
26. Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis.
Tian JC; Liu H; Yan LJ; Ding ZN; Han CL; Tian BW; Tan SY; Dong ZR; Wang DX; Xue JS; Mao XC; Yan YC; Li T
Clin Exp Med; 2023 Oct; 23(6):2115-2129. PubMed ID: 36385419
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis.
Wu J; Ni T; Deng R; Li Y; Zhong Q; Tang F; Zhang Q; Fang C; Xue Y; Zha Y; Zhang Y
Front Immunol; 2023; 14():1065510. PubMed ID: 36993952
[TBL] [Abstract][Full Text] [Related]
28. Comparative safety of immune checkpoint inhibitors and chemotherapy in advanced non-small cell lung cancer: A systematic review and network meta-analysis.
Chen CY; Huang CH; Chen WC; Huang MS; Wei YF
Int Immunopharmacol; 2022 Jul; 108():108848. PubMed ID: 35597121
[TBL] [Abstract][Full Text] [Related]
29. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive analysis of treatment-related adverse events of immunotherapy in advanced gastric or gastroesophageal junction cancer: A meta-analysis of randomized controlled trials.
Yuan H; Duan DD; Zhang YJ
Clin Res Hepatol Gastroenterol; 2022 Dec; 46(10):102031. PubMed ID: 36261109
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews.
Ou SL; Luo J; Wei H; Qin XL; Du SY; Wang S; Jiang Q
Front Immunol; 2022; 13():953761. PubMed ID: 35911744
[TBL] [Abstract][Full Text] [Related]
32. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
[TBL] [Abstract][Full Text] [Related]
33. Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system.
Yan YD; Zhao Y; Zhang C; Fu J; Su YJ; Cui XL; Ma EL; Liu BL; Gu ZC; Lin HW
EClinicalMedicine; 2022 Aug; 50():101535. PubMed ID: 35812997
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
Pillai RN; Behera M; Owonikoko TK; Kamphorst AO; Pakkala S; Belani CP; Khuri FR; Ahmed R; Ramalingam SS
Cancer; 2018 Jan; 124(2):271-277. PubMed ID: 28960263
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
Liu S; Gao W; Ning Y; Zou X; Zhang W; Zeng L; Liu J
Front Immunol; 2022; 13():908173. PubMed ID: 35880172
[TBL] [Abstract][Full Text] [Related]
36. Pneumonitis with combined immune checkpoint inhibitors and chemoradiotherapy in locally advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Yang L; Li B; Xu Y; Zou B; Fan B; Wang C; Wang L
Future Oncol; 2023 May; 19(16):1151-1160. PubMed ID: 37293787
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
Sternschuss M; Yerushalmi R; Saleh RR; Amir E; Goldvaser H
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3369-3379. PubMed ID: 33745080
[TBL] [Abstract][Full Text] [Related]
38. Hematologic side effects of immune checkpoint inhibitor with or without chemotherapy in patients with advanced and metastatic gastrointestinal cancer: A systematic review and network meta-analysis of phase 3 trials.
Hou J; Xie R; Zhang Z; Liu Q; Xiang Q; Cui Y
Front Pharmacol; 2023; 14():1163971. PubMed ID: 37033653
[No Abstract] [Full Text] [Related]
39. Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis.
Tang Q; Wu D; Huang H; Fang H; Wu Y; Liu F; Li N
Front Pharmacol; 2023; 14():1093194. PubMed ID: 37180706
[No Abstract] [Full Text] [Related]
40. Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis.
Chen X; Zhang Z; Hou X; Zhang Y; Zhou T; Liu J; Lin Z; Fang W; Yang Y; Ma Y; Huang Y; Zhao H; Zhang L
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32863271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
